Jin Yan Jin

Jin Yan Jin

PhD, Senior Director and Principal Scientist

Global Head of Modelingand Simulation, and Clin Pharm-Ophth/Neuro, Clinical Pharmacology


Dr. Jin Yan Jin is Senior Director and Principal Scientist in Clinical Pharmacology at Genentech. As Global Head of Modeling and Simulation (M&S), she oversees clinical M&S and data programming for all molecule types in all therapeutic areas. She also oversees overall clinical pharmacology support for all Ophthalmology and Neuroscience molecules in Genentech portfolio as Head of Clin Pharm-Ophth/Neuro.

She has been actively involved in development and registration for many molecules (Atezolizumab, Avastin, Cobimetinib, Herceptin, Pertuzumab, Polatuzumab, Kadcyla, Lucentis, Venetoclax, Vismodegib, Xolair, etc) including rich global regulatory interaction experiences. Before joining Genentech, she worked at Eli Lilly in metabolism and neuroscience areas after Ph.D. and post-doc in Pharmaceutical Sciences from the State University of New York at Buffalo.

Dr. Jin is recognized for her scientific passion of using wide range of quantitative approaches (population modeling, statistical modeling, physiologically-based PK, quantitative system pharmacology, machine learning/artificial intelligence) leveraging diverse data sources (trial data, preclinical data, literature data, real-world data) to impact development of different molecule types (small molecule, mAb, antibody-drug conjugate, bispecifics, new modalities) in many therapeutic areas.

She has strong scientific presence with 78 publications, 40+ oral presentations worldwide, invited panelist on diverse topics, and moderated many scientific conferences, workshops and sessions. Dr. Jin is also a strong leader in the global scientific community. Her recent society leadership roles included as the President (2018) and Board of Director (2014-19) for International Society of Pharmacometrics (ISoP); chair of the 2015 American Conference on Pharmacometrics annual meeting (ACoP); member of Editorial Board for journal CPT:PSP; and member of various committees for American Society for Clinical Pharmacology and Therapeutics (ASCPT) including the Scientific Programming Committee and as membership advocate.